Opaleye Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Opaleye Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-89,000	Closed	-$3.2M	–	55
2015 Q2	$3.2M	Sell	89,000 -131,000	-60%	-$4.08M	1.27%	28
2015 Q1	$6.39M	Sell	220,000 -25,000	-10%	-$661K	2.97%	14
2014 Q4	$5.17M	Hold	245,000	–	–	2.61%	12
2014 Q3	$4.75M	Buy	245,000 +73,400	+43%	+$1.15M	3.7%	10
2014 Q2	$2.68M	Buy	+171,600	New	+$2.77M	2.31%	13

Other funds holding INSY

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Opaleye Management's INSY Position: Q3 2015 in Review

Opaleye Management sold out of Insys Therapeutics, Inc. (INSY) in Q3 2015, closing a stake of 89,000 shares — an estimated $3.2M sold.

Opaleye Management first reported a position in INSY in Q2 2014 and held it in 5 quarters. The position peaked at $6.39M in Q1 2015. 145 funds tracked by Wall St. Rank hold INSY as of Q3 2015.

Opaleye Management reported no remaining Insys Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Opaleye Management sold 89,000 Insys Therapeutics, Inc. shares in Q3 2015, an estimated $3.2M.
Opaleye Management first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
Opaleye Management's Insys Therapeutics, Inc. position peaked at $6.39M in Q1 2015.
145 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2015.

Based on Opaleye Management's 13F filing for Q3 2015, filed 13 Nov 2015.